• e-peas

  Participated · Equity · Jul 2026

  Founded in 2014 and headquartered in Louvain-la-Neuve, e-peas develops and markets ultra-low-power semiconductor technology that enables devices to operate from ambient energy sources such as light, RF, vibration, and heat. Its product portfolio includes energy-harvesting power management ICs, microcontrollers, and sensor solutions backed by about 15 years of research and patented IP. The company says its solutions power high-volume applications including solar-powered remote controls, HVAC systems, cameras, and smart tracking devices for global customers. e-peas aims to extend battery lifespans and eliminate battery replacements for industrial and IoT device designers. Financially, the company has raised multiple rounds including €8 million in 2020, €17.5 million in March 2024, and the recent €19.2 million round to support commercial scaling and international expansion. The firm also maintains offices in Switzerland and the USA.

• CUREosity

  Led · Equity · Jun 2024

  CUREOSITY develops a virtual reality and gamification-based therapy platform, CUREO®, that combines neuroscientific findings — notably neuroplasticity — with clinical therapy experience. The SaaS product offers 50 trainings organized into seven modules and is usable in physiotherapy, occupational therapy, and neuropsychology across all phases and locations. Since market launch the company says it has grown strongly; CUREO® is now in use in almost 200 therapeutic facilities across 24 countries. Management says the idea arose from a personal need of the three founders and that the company will invest heavily in commercial expansion. The firm intends to incorporate emerging technologies into its product roadmap and use the financing to secure financial independence and sustainable operations. The additional capital is intended to further expand CUREO®'s market leadership in VR therapy. CUREosity develops a digitally assisted rehabilitation and training system built on VR technology for cognitive and motor impairments. The founders, who have family members affected, created a new worldwide rehabilitation method informed by current neuroscientific findings and a team of doctors. Its first prototype has shown high acceptance and impressive results in initial clinical practice. The company uses methods to harness neuroplasticity to restore lost abilities and help patients regain independence. CUREosity positions its product to close a growing supply gap as ageing and advances in acute care increase demand; the article cites more than 10 million people in Germany and 700 million worldwide with psychological and neurological impairments. The recent financing is intended to develop the prototype into a marketable product and push for motivating, high-frequency therapy access for patients.

• EyeD Pharma

  Participated · Equity · Dec 2021

  EyeD Pharma develops micro‑implants that provide prolonged, controlled release of ophthalmic drugs, with a current focus on treating glaucoma. The company was founded in 2012 and is based in Liège. Its technology platform supports four product candidates, the most advanced being TimoD. EyeD Pharma plans to launch UniD Manufacturing, a CDMO production unit in the Sart‑Tilman science park, in spring 2022 to accelerate product development and manufacturing. The recent financing is intended to fund clinical trials for TimoD and further development of three other candidates. The company has created 93 jobs in the Liège region since 2012 and expects to add about twenty more roles as it scales. EyeD Pharma develops a microscale controlled-release intraocular implant designed to deliver a few nanograms of medication per day for up to three years to treat glaucoma and other eye conditions. The implant is uniquely small (thickness under 1/3 mm) and is placed inside the eye via a brief surgical intervention, aiming to reduce local side effects and improve adherence compared with daily eye drops. The company was founded in 2012 by Professor Jean-Marie Rakic and other ophthalmologists. Since 2018 EyeD Pharma has also been commercializing ophthalmic surgery equipment to bolster financing. Management plans to accelerate development and production of its implants and expand the team. CEO Melanie Mestdagt stated the most advanced project was scheduled to enter the clinical phase in 2020.

• Hyloris Pharmaceuticals

  Participated · Equity · Apr 2020

  Hyloris Pharmaceuticals is a Liège, Belgium–based specialty pharmaceutical company that identifies underserved medical needs and develops new formulations of existing drugs. Its development strategy is focused on the US FDA 505(b)(2) regulatory pathway, targeting molecules with established safety and efficacy. Product and candidate areas include IV Cardiovascular, other reformulations, and established-market high-barrier generics. The company has two commercial-stage products: Sotalol IV for atrial fibrillation (partnered with AltaThera) and Maxigesic® IV, a non-opioid analgesic co-owned with AFT Pharmaceuticals. Hyloris also has 12 product candidates at various stages of development. In April 2020 Hyloris raised €15m in funding from investors including Scorpiaux, Noshaq, Saffelberg Investments and Nomainvest. The proceeds will support execution of its development and commercialization strategy to bring improved products to market.

No current team members are available.